Researchers have discovered how a cell surface protein called Aplp1 can play a role in spreading material responsible for ...

The addition of adjuvant nivolumab to standard-of-care radiotherapy and cisplatin improved survival for patients with locally ...

In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

Oncology nurses can educate patients on the benefits of subcutaneous administration, including reduced time in the infusion ...

Post-operative nivolumab significantly improved disease-free survival in resected locally advanced head and neck cancer, ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed ...

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

Choueiri, MD. The median progression-free survival was 5.7 months with nivolumab plus tivozanib and 7.4 months with tivozanib alone. Adding nivolumab to treatment with tivozanib does not improve ...

Nivolumab biosimilar is under clinical development by Amgen and currently in Phase III for Metastatic Melanoma.

Shares of I-Mab (NASDAQ:IMAB) jumped 15% in midday trading Monday after the biotech company said it plans to focus on ...

Dr. Eric K. Singhi discusses the benefit of subcutaneous immunotherapy following the FDA approval of subcutaneous Opdivo for ...